MAPT and Alzheimer disease: Data from the TRAILBLAZER-ALZ 2 trial with donanemab, also conducted in an early AD population, significantly lowered amyloid plaque burden, as measured with PET-scan, and slowed clinical progression especially in participants with low/medium brain Tau burden.2